Anti-AAV6 Antibody ELISA Kits Sensitivity Specificity and Application Guides

AAV6 Biology and Gene Therapy Applications

Receptor Binding and Cell Entry

AAV6 utilizes multiple cellular receptors for attachment and entry, contributing to its broad tropism. The primary attachment receptor for AAV6 is heparan sulfate proteoglycan (HSPG), a feature shared with AAV2 but not with all serotypes. The interaction between AAV6 capsid and HSPG is mediated by specific basic amino acid residues on the capsid surface, including arginine and lysine residues at positions 531, 532, and 533. Following initial attachment, AAV6 engages co-receptors including epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) to facilitate internalization via clathrin-mediated endocytosis.

Unique Tropism of AAV6

Human Anti-AAV6 Antibody ELISA Kit

The Human Anti-AAV6 Antibody ELISA Kit is designed for the quantitative or qualitative determination of total anti-AAV6 antibodies (IgG) in human serum, plasma, or other biological fluids. This kit is optimized for high-throughput screening applications in clinical research and regulatory-compliant environments.

Key Features

• High Sensitivity: Detects anti-AAV6 antibodies at concentrations as low as 0.5 ng/mL, ensuring reliable identification of low-titer seropositive samples that may be missed by less sensitive methods such as Western blot or dot blot.
• Broad Dynamic Range: Linear detection range from 0.5 ng/mL to 500 ng/mL, accommodating both seronegative and high-titer samples without the need for extensive dilution optimization.
• Specificity Verified: No cross-reactivity with antibodies against other AAV serotypes (AAV1, AAV2, AAV3, AAV4, AAV5, AAV8, AAV9) or common viral pathogens including adenovirus, herpesvirus, and retrovirus.
• Ready-to-Use Format: Pre-coated plates with purified intact AAV6 particles, pre-diluted standards, and concentrated reagents reduce hands-on time and minimize operator error.
• Qualitative and Quantitative Options: Can be used for binary (positive/negative) patient screening or absolute quantification of antibody concentrations using a standard curve.

Conclusions

AAV6 has emerged as a highly versatile and promising vector for human gene therapy, with unique capabilities for transducing airway epithelium, skeletal and cardiac muscle, and hematopoietic stem cells. However, the presence of preexisting neutralizing antibodies and the potential for treatment-emergent immune responses pose significant challenges to the successful clinical application of AAV6-based therapeutics. The Human Anti-AAV6 Antibody ELISA Kit and Mouse Anti-AAV6 Antibody ELISA Kit provide validated, ready-to-use solutions for serological screening and immunogenicity monitoring, offering high sensitivity, specificity (no cross-reactivity with other AAV serotypes), and reproducibility. These tools enable accurate patient selection, dose optimization, and longitudinal monitoring of immune responses, supporting the development of safer and more effective AAV6-based gene therapies. As the field continues to advance toward clinical applications for cystic fibrosis, muscular dystrophy, and hematologic disorders, reliable anti-AAV6 serology will remain an essential component of successful gene therapy programs.